These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 16540254)
1. Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis. Vogel M; Busse S; Freyberger HJ; Grabe HJ Med Hypotheses; 2006; 67(2):354-8. PubMed ID: 16540254 [TBL] [Abstract][Full Text] [Related]
2. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Guillin O; Demily C; Thibaut F Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic possibilities of cysteamine in the treatment of schizophrenia. Pae CU; Lee C; Paik IH Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669 [TBL] [Abstract][Full Text] [Related]
5. D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+ -T cells. Boneberg EM; von Seydlitz E; Pröpster K; Watzl H; Rockstroh B; Illges H J Neuroimmunol; 2006 Apr; 173(1-2):180-7. PubMed ID: 16376996 [TBL] [Abstract][Full Text] [Related]
6. [New pharmacological approaches to the treatment of schizophrenia]. Uzbay IT Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368 [TBL] [Abstract][Full Text] [Related]
7. Chronic amphetamine treatment reduces NGF and BDNF in the rat brain. Angelucci F; Gruber SH; El Khoury A; Tonali PA; Mathé AA Eur Neuropsychopharmacol; 2007 Dec; 17(12):756-62. PubMed ID: 17434716 [TBL] [Abstract][Full Text] [Related]
9. Biochemistry and the schizophrenia. Old concepts and new hypothesis. Berger PA J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786 [TBL] [Abstract][Full Text] [Related]
10. Age-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic mice. Schulte-Herbrüggen O; Eckart S; Deicke U; Kühl A; Otten U; Danker-Hopfe H; Abramowski D; Staufenbiel M; Hellweg R J Neurosci Res; 2008 Sep; 86(12):2774-83. PubMed ID: 18438945 [TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway. Guillin O; Griffon N; Diaz J; Le Foll B; Bezard E; Gross C; Lammers C; Stark H; Carroll P; Schwartz JC; Sokoloff P Int Rev Neurobiol; 2004; 59():425-44. PubMed ID: 15006497 [No Abstract] [Full Text] [Related]
13. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Ohara K Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889 [TBL] [Abstract][Full Text] [Related]
14. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Shoval G; Weizman A Eur Neuropsychopharmacol; 2005 May; 15(3):319-29. PubMed ID: 15820422 [TBL] [Abstract][Full Text] [Related]
15. A critique of the dopamine hypothesis of schizophrenia and psychosis. Moncrieff J Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420 [TBL] [Abstract][Full Text] [Related]
16. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Meyer U; Feldon J Behav Brain Res; 2009 Dec; 204(2):322-34. PubMed ID: 19154759 [TBL] [Abstract][Full Text] [Related]